Results 81 to 90 of about 5,312,533 (302)

Clinical proteomics for precision medicine: the bladder cancer case [PDF]

, 2017
Precision medicine can improve patient management by guiding therapeutic decision based on molecular characteristics. The concept has been extensively addressed through the application of –omics based approaches.
Frantzi, Maria, Latosinska, Agnieszka, Merseburger, Axel S., Mischak, Harald, Vlahou, Antonia   +4 more
core   +1 more source

Trihalomethanes in Drinking Water and Bladder Cancer Burden in the European Union

Environmental Health Perspectives, 2020
Background: Trihalomethanes (THMs) are widespread disinfection by-products (DBPs) in drinking water, and long-term exposure has been consistently associated with increased bladder cancer risk.
Iro Evlampidou, Laia Font-Ribera, D. Rojas-Rueda, E. Gracia-Lavedán, N. Costet, N. Pearce, P. Vineis, J. Jaakkola, F. Delloye, K. Makris, E. Stephanou, S. Kargaki, F. Kožíšek, T. Sigsgaard, B. Hansen, J. Schullehner, Ramon Nahkur, C. Galey, C. Zwiener, M. Vargha, E. Righi, G. Aggazzotti, G. Kalnina, R. Gražulevičienė, K. Polańska, Dasa Gubkova, K. Bitenc, E. Goslan, M. Kogevinas, C. Villanueva   +29 more
semanticscholar   +1 more source

Differential Protein Expression Patterns of HOXA13 and HOXB13 Are Associated with Bladder Cancer Progression

Diagnostics, 2023
Bladder cancer is a common urological cancer and has the highest recurrence rate of any cancer. The aim of our study was to profile and characterize the protein expression of homeobox A13 (HOXA13) and homeobox B13 (HOXB13) genes in Malaysian bladder ...
Fee-Wai Chin, Huzlinda Hussin, De-Ming Chau, Teng-Aik Ong, Rosna Yunus, Azad Hassan Abdul Razack, Khatijah Yusoff, Soon-Choy Chan, Abhi Veerakumarasivam   +8 more
doaj   +1 more source

Kdm6a Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with p53 Dysfunction

Clinical Cancer Research, 2020
Purpose: Epigenetic deregulation is deeply implicated in the pathogenesis of bladder cancer. KDM6A (Lysine (K)-specific demethylase 6A) is a histone modifier frequently mutated in bladder cancer.
K. Kobatake, K. Ikeda, Y. Nakata, N. Yamasaki, Takeshi Ueda, A. Kanai, K. Sentani, Y. Sera, Tetsutaro Hayashi, Miho Koizumi, Y. Miyakawa, T. Inaba, Y. Sotomaru, O. Kaminuma, T. Ichinohe, Z. Honda, W. Yasui, S. Horie, P. Black, A. Matsubara, H. Honda   +20 more
semanticscholar   +1 more source

Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors [PDF]

, 2018
To compare long-term overall survival (OS) in patients with G1 and G2 grade Ta bladder cancer after transurethral resection of bladder tumors (TURBTs).
Balan, Daniel, Borda, Angela, Busetto, Gian Maria, Chibelean, Calin Bogdan, Cioffi, Antonio, De Berardinis, Ettore, Del Giudice, Francesco, Ferro, Matteo, Lucarelli, Giuseppe, Martha, Orsolya, Matei, Victor Deliu, Porav-Hodade, Daniel, Pytel, Akos, Sin, Anca, Tataru, Sabin, Vartolomei, Mihai Dorin, Voidezan, Septimiu   +16 more
core   +2 more sources

Detection of genome-wide methylation changes in bladder cancer by long-read sequencing of urinary DNA

Clinical Epigenetics
Background Non-invasive urine tests for bladder cancer (BC) could reduce dependence on flexible cystoscopy for diagnosis and surveillance. Most recent developments in urine testing are based on targeted detection of genomic and/or epigenomic markers.
Anshita Goel, Benjamin J. Tura, Joanne D. Stockton, Nicholas Tovey, Luke Ames, Andrew D. Beggs, Maurice P. Zeegers, Nicholas D. James, K. K. Cheng, Richard T. Bryan, Douglas G. Ward, Roland Arnold   +11 more
doaj   +1 more source

Supplementation of Probiotic Butyricicoccus pullicaecorum Mediates Anticancer Effect on Bladder Urothelial Cells by Regulating Butyrate-Responsive Molecular Signatures

Diagnostics, 2021
In bladder cancer, urothelial carcinoma is the most common histologic subtype, accounting for more than 90% of cases. Pathogenic effects due to the dysbiosis of gut microbiota are localized not only in the colon, but also in regulating bladder cancer ...
Yen-Chieh Wang, Wei-Chi Ku, Chih-Yi Liu, Yu-Che Cheng, Chih-Cheng Chien, Kang-Wei Chang, Chi-Jung Huang   +6 more
doaj   +1 more source

Identification of a Nomogram from Ferroptosis-Related Long Noncoding RNAs Signature to Analyze Overall Survival in Patients with Bladder Cancer [PDF]

, 2021
Yuanshan Cui, Zhongbao Zhou, Yumeng Chai, Xuanyan Che, Yong Zhang   +4 more
openalex   +1 more source

Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes after Surgery [PDF]

, 2011
Objective: The aim of this study was to externally validate the prognostic value of concomitant urothelial carcinoma in situ (CIS) in radical cystectomy (RC) specimens using a large international cohort of bladder cancer patients. Methods: The records of
Colin P. Dinney, Derya Tilki, Eila Skinner, Francesco Montorsi, Giacomo Novara, Guru Sonpavde, Habuchi T, Hans-Martin Fritsche, Hendrik Isbarn, Jonathan I. Izawa, Knowles MA, Lamm DL, Patrick J. Bastian, Philipp Nuhn, Pierre I. Karakiewicz, Robert S. Svatek, Rosin MP, Sarkis AS, Shahrokh F. Shariat, Skinner DG, Spruck, Stefan C. Müller, Utz DC, Vincenzo Ficarra, Wassim Kassouf, Yves Fradet, Zincke H   +26 more
core   +1 more source

Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience

Frontiers in Oncology
IntroductionEnfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to a human monoclonal antibody targeting nectin-4.
Evangelia Vlachou, Evangelia Vlachou, Burles Avner Johnson, Burles Avner Johnson, David McConkey, David McConkey, Yuezhou Jing, Andres Matoso, Andres Matoso, Andres Matoso, Andres Matoso, Noah M. Hahn, Noah M. Hahn, Noah M. Hahn, Jean Hoffman-Censits, Jean Hoffman-Censits, Jean Hoffman-Censits   +16 more
doaj   +1 more source